Immünosüpresif, Biyolojik ve Küçük Molekül Tedaviler Öncesi Hasta Bilgilendirme
Özet
İmmünsüpresif, biyolojik ve küçük molekül tedaviler; inflamatuvar bağırsak hastalığı (İBH), otoimmün hepatit, primer biliyer kolanjit, IgG4 ilişkili hastalık ve karaciğer nakli gibi durumların yönetiminde modern gastroenteroloji ve hepatolojinin temel taşlarıdır. Bu ajanların en sık ve en kritik yan etkisi, konak savunmasının zayıflamasına bağlı enfeksiyon yatkınlığıdır; ayrıca uzun dönemde malignite ve de novo otoimmün süreç riski taşırlar. Bu nedenle tedaviye başlamadan önce sistematik bir risk değerlendirmesi, latent enfeksiyon taraması (tüberküloz, hepatit B/C, HIV, VZV) ve doğru zamanlanmış aşılama, güvenli tedavinin ön koşuludur. Bu bölümün amacı; bu tedavilere başlanacak erişkin hastalarda ilaç sınıflarının temel özelliklerini, tedavi öncesi risk değerlendirmesini, enfeksiyon tarama ve profilaksi protokollerini, güncel aşılama ilkelerini (canlı/cansız aşı zamanlaması, pnömokok, influenza, hepatit B, zoster) ve hasta bilgilendirmesini standart bir çerçevede sunmaktır. Öneriler ECCO, AASLD, ESsCD ve güncel bağışıklama (ACIP) kılavuzlarına dayanır. Ayrıca standart hasta bilgilendirme metni, sık sorulan sorular ve acil başvuru kriterlerine yer verilmiştir.
Immunosuppressive, biologic and small-molecule therapies are cornerstones of modern gastroenterology and hepatology in inflammatory bowel disease (IBD), autoimmune hepatitis, primary biliary cholangitis, IgG4-related disease and liver transplantation. Their most frequent and critical adverse effect is increased susceptibility to infection due to weakened host defense; they also carry a long-term risk of malignancy and de novo autoimmune processes. Therefore, systematic pre-treatment risk assessment, screening for latent infections (tuberculosis, hepatitis B/C, HIV, VZV) and appropriately timed vaccination are prerequisites for safe therapy. This chapter provides a standardized framework covering drug-class characteristics, pre-treatment risk stratification, infection screening and prophylaxis protocols, current vaccination principles (timing of live/inactivated vaccines, pneumococcal, influenza, hepatitis B, zoster) and patient education, in accordance with ECCO, AASLD, ESsCD and current immunization (ACIP) guidelines, together with standardized patient information, FAQs and emergency criteria.
Referanslar
Gordon H, Minozzi S, Kopylov U, et al. ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment. J Crohns Colitis. 2024;18(10):1531-1555.
Kucharzik T, Ellul P, Greuter T, et al. ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inf-lammatory Bowel Disease. J Crohns Colitis. 2021;15(6):879- 913.
Rahier JF, Magro F, Abreu C, et al. Second European eviden¬ce-based consensus on the prevention, diagnosis and mana¬gement of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8(6):443-468.
Mack CL, Adams D, Assis DN, et al. Diagnosis and Manage¬ment of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the AASLD. Hepato¬logy. 2020;72(2):671-722.
Lindor KD, Bowlus CL, Boyer J, et al. Primary Biliary Cholan¬gitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69(1):394- 419.
Al-Toma A, Branchi F, Zingone F, et al. European Society for the Study of Coeliac Disease (ESsCD) 2025 Updated Guideli¬nes on the Diagnosis and Management of Coeliac Disease in Adults. United European Gastroenterol J. 2026;14(2):e70195.
Te HS, Agopian VG, Demetris AJ, et al. AASLD/AST Prac¬tice Guideline on adult liver transplantation: Diagnosis and management of graft-related complications. Liver Transpl. 2026;32(3):444-490.
Ananthakrishnan AN, Nguyen GC, Bernstein CN. AGA Cli¬nical Practice Update on Management of Inflammatory Bowel Disease in Elderly Patients: Expert Review. Gastroenterology. 2021;160(1):445-451.
Peyrin-Biroulet L, Chapman JC, Colombel JF, et al. Risanki¬zumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease. N Engl J Med. 2024;391(3):213-223.
Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis (ORAL Surveillance). N Engl J Med. 2022;386(4):316-326.
Kobayashi M, Leidner AJ, Gierke R, et al. Expanded Recom-mendations for Use of Pneumococcal Conjugate Vaccines Among Adults Aged ≥50 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024. MMWR Morb Mortal Wkly Rep. 2025;74(1):1-8.
Winthrop KL, Novosad SA, Baddley JW, et al. Opportunistic infections and biologic therapies in immune-mediated inf¬lammatory diseases: consensus recommendations for infecti¬on reporting during clinical trials and postmarketing surveil¬lance. Ann Rheum Dis. 2015;74(12):2107-2116.
Löhr JM, Beuers U, Vujasinovic M, et al. European Guideline on IgG4-related digestive disease — UEG and SGF eviden¬ce-based recommendations. United European Gastroenterol J. 2020;8(6):637-666.
Crabb DW, Im GY, Szabo G, et al. Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the AASLD. Hepatology. 2020;71(1):306-333.
Sandborn WJ, Feagan BG, Hanauer S, et al. Long-Term Effi¬cacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis. J Crohns Colitis. 2021;15(7):1120-1129.
T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü. Tüber¬küloz Tanı ve Tedavi Rehberi. Ankara; 2026.
Ballow M, Fleisher TA. Secondary immunodeficiency indu¬ced by biologic therapies. UpToDate; 2026.
